VYNE Therapeutics — raw details

Highlights

1 patent

About

Therapies for the Treatment of Immuno-inflammatory Conditions

VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.

VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.

The company was formed from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.

Identity

Name	VYNE Therapeutics
Slug	vyne-therapeutics
Former names	Foamix Pharmaceuticals, Menlo Therapeutics
Type / kind	startup
Crunchbase ID	foamix
Source _id	agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6sq_wKDA

Status

Status	acquired
Status reason	Acquired (Inactive) by Menlo Therapeutics on Nov 2019 - ceased to operate
Last update	2026-05-17

Location

HQ country code	IL
HQ region/district	Center District
HQ city	Ness Ziona
HQ address	Golda Me'ir Street 7, Ness Ziona, Israel

Web & social

LinkedIn	https://www.linkedin.com/company/68042510
Twitter / X	https://twitter.com/VYNEtx
Facebook	https://www.facebook.com/VYNEtx

Classifications

Primary sector Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

BiologicalsMolecules

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business models

B2B

Funding

Total raised	$180.0M
Current stage	Public
Market cap	$19.3M

Raw source document

Show full JSON (0 KB)

{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}